HK1038497A1 - Methods for treating diabetes by inhibiting gdf-8 - Google Patents

Methods for treating diabetes by inhibiting gdf-8

Info

Publication number
HK1038497A1
HK1038497A1 HK01105702.7A HK01105702A HK1038497A1 HK 1038497 A1 HK1038497 A1 HK 1038497A1 HK 01105702 A HK01105702 A HK 01105702A HK 1038497 A1 HK1038497 A1 HK 1038497A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating diabetes
inhibiting gdf
gdf
inhibiting
Prior art date
Application number
HK01105702.7A
Other languages
English (en)
Inventor
Gideon Strassmann
Li-Fang Liang
Stavros Topouzis
Original Assignee
Metamorphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metamorphix Inc filed Critical Metamorphix Inc
Publication of HK1038497A1 publication Critical patent/HK1038497A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01105702.7A 1998-05-06 2001-08-14 Methods for treating diabetes by inhibiting gdf-8 HK1038497A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8449098P 1998-05-06 1998-05-06
PCT/US1999/010089 WO1999056768A1 (en) 1998-05-06 1999-05-06 Methods for treating diabetes by inhibiting gdf-8

Publications (1)

Publication Number Publication Date
HK1038497A1 true HK1038497A1 (en) 2002-03-22

Family

ID=22185291

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105702.7A HK1038497A1 (en) 1998-05-06 2001-08-14 Methods for treating diabetes by inhibiting gdf-8

Country Status (9)

Country Link
US (6) US6368597B1 (de)
EP (1) EP1075272B1 (de)
JP (1) JP4544742B2 (de)
AU (1) AU765214B2 (de)
CA (1) CA2331410C (de)
DE (1) DE69941116D1 (de)
ES (1) ES2330062T3 (de)
HK (1) HK1038497A1 (de)
WO (1) WO1999056768A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1465911B1 (de) * 2001-12-17 2008-03-26 Metabolex, Inc. Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
PL375045A1 (en) 2002-02-21 2005-11-14 Wyeth Gasp1: a follistatin domain containing protein
BR0307871A (pt) * 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
US7572599B2 (en) * 2002-09-16 2009-08-11 The Johns Hopkins University School Of Medicine Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2513086A1 (en) * 2002-12-19 2004-07-08 Scios Inc. Treatment of obesity and associated conditions with tgf-.beta. inhibitors
MEP57508A (en) * 2002-12-20 2011-05-10 Amgen Inc Binding agents which inhibit myostatin
MXPA05012965A (es) 2003-06-02 2006-03-09 Wyeth Corp Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello.
CN1902221A (zh) * 2003-12-31 2007-01-24 先灵-普劳有限公司 基于中和表位的生长增强疫苗
US7456149B2 (en) * 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
ATE557042T1 (de) * 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
EP1778275A2 (de) * 2004-08-12 2007-05-02 Wyeth Kombinationstherapie für diabetes, adipositas und herz-kreislauf-erkrankungen unter verwendung von gdf-8-hemmern
MX2007008132A (es) * 2004-12-30 2007-07-20 Schering Plough Ltd Vacuna para aumentar el crecimiento basada en epitopes neutralizantes.
EP1864139A2 (de) * 2005-03-23 2007-12-12 Wyeth Nachweis einer immunreaktion auf gdf-8-modulierende wirkstoffe
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
JP5415071B2 (ja) 2005-08-19 2014-02-12 ワイス・エルエルシー Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
ES2533464T3 (es) * 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CA2856436A1 (en) * 2005-12-06 2007-06-14 Amgen Inc. Uses of myostatin antagonists
PT2066695E (pt) 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
EP2434010A4 (de) 2009-05-22 2013-02-27 Erina Co Inc Vorbeugender und/oder therapeutischer wirkstoff für das stoffwechselsyndrom
JP5858929B2 (ja) * 2010-01-15 2016-02-10 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｄｅｘおよびｇｄｆ８を用いたスクリーニングアッセイ
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
NZ608206A (en) 2010-08-16 2015-02-27 Amgen Inc Antibodies that bind myostatin, compositions and methods
LT2780368T (lt) 2011-11-14 2018-03-12 Regeneron Pharmaceuticals, Inc. Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a
MY177331A (en) * 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
TWI694085B (zh) 2012-09-13 2020-05-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
CN104931327B (zh) * 2015-03-24 2018-10-19 重庆医科大学 微米级生物材料石蜡切片方法
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
AU2019226551A1 (en) 2018-03-01 2020-10-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
JP7411563B2 (ja) 2018-10-12 2024-01-11 シーシーアイホールディングス株式会社 クラスｉのグルコーストランスポーター（ｇｌｕｔ）の発現誘導剤、並びにこれを用いた医薬組成物および飲食品組成物
CN110408616B (zh) * 2019-07-09 2021-06-15 中南民族大学 GLUT4基因敲除的sgRNA、A549细胞系及其构建方法
US20220340668A1 (en) 2019-09-03 2022-10-27 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
AU6274298A (en) * 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
WO1999006559A1 (en) * 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
CN1384757A (zh) * 1999-07-20 2002-12-11 法麦克萨有限公司 下调gdf－8活性的方法

Also Published As

Publication number Publication date
EP1075272B1 (de) 2009-07-15
AU4183299A (en) 1999-11-23
DE69941116D1 (de) 2009-08-27
US6368597B1 (en) 2002-04-09
AU765214B2 (en) 2003-09-11
US20160122424A1 (en) 2016-05-05
WO1999056768A1 (en) 1999-11-11
CA2331410C (en) 2009-07-14
ES2330062T3 (es) 2009-12-03
US20090035297A1 (en) 2009-02-05
US9150643B2 (en) 2015-10-06
JP2002513768A (ja) 2002-05-14
US20020031517A1 (en) 2002-03-14
US20060121035A1 (en) 2006-06-08
US20180134779A1 (en) 2018-05-17
EP1075272A1 (de) 2001-02-14
JP4544742B2 (ja) 2010-09-15
CA2331410A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
HK1038497A1 (en) Methods for treating diabetes by inhibiting gdf-8
AU2001231104A1 (en) Methods for treating diabetes
IL122718A0 (en) Methods for treating diabetes
AU6200999A (en) Treatment for fabrics
GB9821218D0 (en) Treatment for fabrics
EP1215963A4 (de) Verfahren zur behandlung neuropathischer schmerzen unter verwendung von heteroarylmethansulfonamiden
AU3529399A (en) Well treatment for water restriction
ZA200202843B (en) Method for improving growth.
GB9821217D0 (en) Treatment for substrates
AU6263899A (en) Method for treating androgen-related conditions
IL142248A0 (en) Methods for treating sepsis
AU2777999A (en) Method for treating plants
IL137828A0 (en) Process for preparing protected 4-aminomethyl-pyrrolidin-3-one
HK1039449A1 (zh) 治療多發性硬化的方法
ZA994105B (en) Method for treating glaucoma.
AU2482400A (en) Advanced treatment for produced water
GB0009367D0 (en) Method for protecting bytecode
PL343313A1 (en) Methods for inhibiting mrp1
AU5898200A (en) Improved system for treating meat
HK1033551A1 (en) Method for treating copd.
PL343312A1 (en) Methods for inhibiting mrp1
AU1112500A (en) Methods for inhibiting diabetic complications
EP1199347A4 (de) Verfahren zur behandlung von rohöl
PL343320A1 (en) Methods for inhibiting mrp1
HUP0102016A3 (en) Method for copperplating substrates

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190505